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RESEARCH
A nationwide study on concordance 
with multimodal treatment guidelines in bipolar 
disorder
Joannes W. Renes1*, Eline J. Regeer1, Adriaan W. Hoogendoorn2, Willem A. Nolen3 and Ralph W. Kupka1,2
Abstract 
Background: Most previous studies on concordance with treatment guidelines for bipolar disorder focused on phar-
macotherapy. Few studies have included other treatment modalities.
Aims: To study concordance with the Dutch guideline of various treatment modalities in outpatient treatment set-
tings for patients with bipolar disorder and to identity factors associated with concordance.
Methods: A nationwide non-interventional study using psychiatrists’ and patients’ surveys.
Results: 839 patients with bipolar or schizoaffective disorder bipolar type were included. Concordance with the 
guideline was highest for participation of a psychiatrist in the treatment (98%) and for maintenance pharmacotherapy 
(96%), but lower for supportive treatment (73.5%), use of an emergency plan (70.6%), psychotherapy (52.2%), group 
psychoeducation (47.2%), and mood monitoring (47%). Presence of a written treatment plan, a more specialized treat-
ment setting, more years of education, and diagnosis of bipolar I disorder versus bipolar II, bipolar NOS, or schizoaffec-
tive disorder were significantly associated with better concordance.
Conclusion: In contrast to pharmacotherapy, psychosocial treatments are only implemented to a limited extend 
in everyday clinical practice in bipolar disorder. More effort is needed to implement non-pharmacological guideline 
recommendations for bipolar disorder.
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Background
To improve the quality of care, several guidelines for 
the treatment of bipolar disorder (BD) have been pub-
lished in the past two decades, including in the Nether-
lands (Kupka et  al. 2015; Nolen et  al. 2008). Studies on 
the naturalistic treatment of BD show that concordance 
with these guidelines varies considerably from less than 
50% (Altinbas et  al. 2011; Baek et  al. 2014; Busch et  al. 
2007; Lim et  al. 2001), 50–70% (Arvilommi et  al. 2007; 
Bauer et al. 2009; Farrelly et al. 2006; Freeland et al. 2015; 
Huang et al. 2014; Marcus et al. 1999; Simon et al. 2004; 
Smith et al. 2008; Wang et al. 2014a, 2015), or up to 90% 
(Altinbas et al. 2011; Farrelly et al. 2006; Kilbourne et al. 
2005; Paterniti and Bisserbe 2013; Unutzer et  al. 2000; 
Walpoth-Niederwanger et  al. 2012; Wang et  al. 2014b) 
on the primary outcome measure of concordance. These 
concordance rates are difficult to compare due to differ-
ences in study design, treatment settings, and in what 
phase of the illness concordance was studied. Most stud-
ies focused on pharmacotherapy only (including moni-
toring of plasma levels), and were retrospective in design. 
Few studies have included other treatment modalities, 
such as psychoeducation or psychotherapy, or visits with 
health care providers (Busch et  al. 2007; Farrelly et  al. 
2006; Kilbourne et al. 2005; Unutzer et al. 2000).
In these naturalistic studies on concordance with treat-
ment guidelines, factors that have been found to be of 
influence are type of mood episode (Baek et al. 2014; Far-
relly et al. 2006; Huang et al. 2014; Paterniti and Bisserbe 
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2013), psychotic features (Altinbas et al. 2011; Lim et al. 
2001), bipolar disorder subtype (Simon et  al. 2004), age 
at onset (Dennehy et al. 2007), rapid cycling (Arvilommi 
et  al. 2007), treatment setting (Arvilommi et  al. 2007; 
Busch et  al. 2007), race (Kilbourne et  al. 2005), and 
higher medical complexity in elderly patients (Huang 
et al. 2014).
In 2008 a revised guideline on the treatment of bipolar 
disorder in the Netherlands was published (Nolen et  al. 
2008). In this paper we present the outcomes of a nation-
wide naturalistic prospective study on treatment practice 
and concordance with this Dutch guideline in various 
treatment settings for patients with BD or schizoaffec-
tive disorder, bipolar type (SZA). We hypothesized that 
the guideline would be better implemented in centers 
specialized in the treatment of mood disorders, and in 
patients with bipolar I disorder (BD I) versus those with 
bipolar II disorder (BD II), bipolar disorder NOS (BD 
NOS), or SZA. Since BD I is more clearly defined by the 
lifetime occurrence of full manic episodes, this diagnosis 
will represent a more homogeneous group of patients, 
for which providers probably better recognize treatment 
recommendations in the guideline. Moreover, guidelines 
often take BD I as their main focus. We further examined 
the relationship of demographic, illness, and treatment 
variables with concordance with the guideline.
Methods
The Treatment of Bipolar Disorder in the Netherlands 
study (TBDN) is a nationwide, multicenter, non-inter-
vention study on concordance with guideline recommen-
dations for the long-term treatment of BD and SZA in 
mental health outpatient treatment settings (Renes et al. 
2014). The study was performed between December 2009 
and June 2014.
Selection of psychiatrists and patients
Between December 2009 and February 2010 all psychi-
atrists registered as member of the Dutch Psychiatric 
Association received a short survey about their treat-
ment setting and whether they would be willing to par-
ticipate in this study. All psychiatrists who indicated that 
they were treating adult patients with BD or SZA in an 
outpatient setting and were interested in participating in 
the study, received a questionnaire about their treatment 
setting, organization of care, and the number of patients 
currently in treatment for BD or SZA. Furthermore, they 
were asked to send a letter to all these patients inviting 
them to participate in the study.
All patients who returned an informed consent form 
were sent two questionnaires: one for themselves and one 
for a spouse, relative or significant other. The patients’ 
questionnaire concerned care they had received in the 
previous 12 months or earlier for some treatment modal-
ities, lifetime illness characteristics, clinical outcome, 
quality of life and functioning, satisfaction with care, 
and adherence to treatment. For each patient a clini-
cal diagnosis, according to DSM-IV-TR (American Psy-
chiatric Association 2000), was supplied by the treating 
psychiatrist, including comorbid diagnoses. The study 
was approved by the Medical Ethical Committee of the 
University Medical Center Utrecht, the Netherlands, 
and independently reviewed by the scientific committees 
of the two main participating research centers, Altrecht 
Institute for Mental Health Care, Utrecht, the Nether-
lands, and GGZ inGeest/VU University Medical Center, 
Amsterdam, the Netherlands. All participating patients 
gave written informed consent.
Outcome measures
Treatment modalities
Patients were asked to tick the medication they were cur-
rently using from a list of maintenance medications (lith-
ium, carbamazepine, valproate, lamotrigine, olanzapine, 
quetiapine, risperidone, or aripiprazole), and to add any 
other medication they were currently using for BD, and 
were asked if, and with what frequency, laboratory tests 
were part of the treatment with lithium, valproate or car-
bamazepine. For psychosocial treatments, patients were 
asked if they ever had participated in a group psychoedu-
cation program, if they had ever received psychotherapy, 
and if so, whether they had received it in the previous 
year, if they had received supportive treatment in the 
previous year, if they had an emergency plan on how to 
deal with early symptoms of an impending mood epi-
sode, and if they regularly monitored their mood by com-
pleting prospective LifeCharts according to the NIMH 
Life-Chart Method (Leverich and Post 1998), which is 
well-known in the Netherlands.
Measurement of concordance with the Dutch guideline
In the Dutch guideline recommendations may differ 
for patients with specific clinical profiles. For our study 
we distinguished four clinical profiles. Table  1 indicates 
which treatment modalities are, and which are not, rec-
ommended to be part of the treatment for patients with 
these profiles.
Maintenance pharmacotherapy is recommended for 
patients after three or more mood episodes, and for 
patients after two episodes if at least one of the episodes 
was severe, or when the patient has a first degree rela-
tive with BD. Furthermore, maintenance pharmacother-
apy may be considered: (1) after a single severe manic 
episode, (2) after a single manic episode of any severity 
and having a first degree relative with BD, or (3) after 
two non-severe episodes without a family history of BD. 
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Finally, maintenance pharmacotherapy is not recom-
mended for patients with a single non-severe manic epi-
sode in the absence of a first degree relative with BD.
To assess concordance with the Dutch guideline, a 
composite score ranging from 0 to 100 for the degree of 
concordance was developed based on the sum of scores 
for each treatment modality, taking into account an 
assumed impact factor of each treatment modality on 
treatment outcome as determined by consensus among 
the authors (JR, ER, WN, RK), when taking into account 
the level of scientific evidence of recommendations as 
described in the guideline. Of notice, WN and RK had 
been involved in the development of the guideline. The 
impact factors were rated as follows: pharmacotherapy 
40 points, group psychoeducation 20, psychotherapy 20, 
participation of a psychiatrist 5, having an emergency 
plan on how to deal with emerging symptoms 5, mood 
monitoring 5, and supportive treatment 5 points.
If, according to the guideline, a treatment modality 
was recommended and accordingly applied, points were 
added to the total score; and similarly if a treatment 
modality was not recommended and accordingly not 
applied. If a treatment modality was recommended but 
not applied, or applied despite not being recommended, 
no points were added. The latter was based on the 
assumption that a more intensive treatment is not nec-
essarily beneficial and might even pose a psychological 
or biological burden on the patient. No points were sub-
tracted in case of non-concordance.
Assessment of symptoms and illness characteristics
The Quick Inventory of Depressive Symptomatology 
(QIDS) (Rush et  al. 1996), and the Altman Self-Rating 
Mania Scale (ASRM) (Altman et  al. 1997), were part of 
the patient questionnaire to measure current severity of 
mood symptoms. The questionnaire also addressed vari-
ous lifetime illness characteristics. Because these data 
were obtained through self-reporting, some data could 
be missing or conflicting. When data were conflicting, 
consensus was first reached between the first two authors 
(JR, ER). The other authors (WN, RK) were consulted 
when necessarily. Data that remained inconclusive were 
excluded from analysis.
Statistical analyses
SPSS 22 was used for statistical analysis. Descriptive sta-
tistics were used for demographics and illness charac-
teristics of the sample. Relationships with the total score 
of concordance were tested using simple and multiple 
regression analyses.
Table 1 Treatment modalities that  are recommended by  the  Dutch guideline for  the  treatment of  BD in  patients 
with differential clinical profiles
a “+” indicates the modality is recommended to be part of the treatment in case of that particular clinical profile, and “−” indicates the modality is not recommended 
to be part of the treatment
b Patients with BD should have at least one visit/year with a psychiatrist or physician, when health care providers other than a psychiatrist/physician are part of the 
treatment team
c For these patients an emergency plan is recommended as optional
d At least three visits with a psychiatrist or mental health nurse in the previous year




















 Participation of a  psychiatristb + + + +
 Group psychoeducation + + + +
 Emergency plan +/−c +/−c + +
 Maintenance pharmaco-
therapy
– + + +
 Life charting − − + +
 Supportive  treatmentd − − + +
 Psychotherapye − − − +
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Total number of psychiatrists that returned the irst 
questionnaire: 123 (22.5%)
24 not eligible to participate
(20 no treatment in ambulatory settings, 1 only 
child psychiatry, 1 no treatment of bipolar patients, 
1 loss of contact)
Eligible to participate: 99 (18%)
2 withdrawal from study 
(1 ending practice, 1 logistical problems)
Total number of psychiatrists 
That invited  patients to participate: 97
29 psychiatrists without inclusion of patients
Number of psychiatrists with inclusion of patients: 
68 (12.4%)
• specialized centers for mood disorders: 34
• non-specialized centers: 34
Short questionnaire to all members of Dutch 
Association of Psychiatry: 2525
Interested in further research: 616
Eligible to participate : 541
Including 6 additionally after the irst short 
questionnaire: 547 
Response: 1579 
Total number of patient that returned the informed 
consent form: 1136 Drop-out: 12 
(4 withdrawal informed consent, 
3 not in treatment with participating psychiatrist, 
4 various administrative reasons, 
1 participating second time through a different 
psychiatrist)
Number of patients with informed consent and 
known DSM diagnosis: 1124
Number of patients that returned the baseline 
questionnaire: 845
Exclusion of patients with a depressive or 
cyclothymic disorder: 6
Number of patients included for analysis: 839
639 from specialized mood disorder centers
200 from non-specialized centers
Approximation number of patients invited to the 
study: 3250*
* based on anonymous logs with number of patients invited by psychiatrists, or number of letters for patients 
provided to the psychiatrists 
Fig. 1 Inclusion of psychiatrists and patients
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Results
Inclusion
The inclusion of psychiatrists and patients is presented in 
Fig. 1.
Socio‑demographic and illness characteristics
Five hundred and fifty-five respondents (66.2%) were 
women. The average age was 49.5  years (s.d. 11.2). Five 
hundred and one out of 833 (60.1%) respondents were 
married or living together. The mean years of education 
(n = 837) was 16.1  years (s.d. 4.3). Diagnoses were BD I 
(n = 551; 65.7%), BD II (n = 211; 25.1%), BD NOS (n = 32; 
3.8%), and SZA (n = 45; 5.4%). At least one comor-
bid psychiatric diagnosis was present in 238 respond-
ents (28.4%). The mean duration of illness (n = 712) 
was 23.8  years (s.d. 12.3). The average age at onset for 
(hypo)manic symptoms was 30.1  years (s.d. 11.8), and 
for depressive symptoms 26.1 years (s.d. 11.7). Only nine 
respondents (1.1%) experienced one single manic epi-
sode, 28 (3.3%) had two mood episodes, all other 718 
respondents (85.6%) had three or more mood episodes. 
Data on total lifetime number of mood episodes were 
inconclusive or missing in 84 respondents (10%). Hospi-
tal admission because of a mood episode was reported by 
532 (63.4%) respondents. Data on admission were miss-
ing in 65 respondents (7.7%). Of the respondents, 283 
(33.7%) had a first degree relative with bipolar disorder.
Treatments
The number of respondents receiving maintenance phar-
macotherapy and various forms of psychosocial treat-
ments is reported in Table 2.
Maintenance pharmacotherapy
Lithium, carbamazepine, valproate, lamotrigine or an 
antipsychotic as maintenance medication was used by 
804 (96.1%) respondents. Of the remaining 32 (3.9%) who 
currently did not use any pharmacotherapy, 15 had BD 
I, 13 BD II, three BD NOS, and one SZA; all reported at 
least two previous mood episodes (data missing in one), 
Table 2 Elements of current treatment as reported by the patients
a Sample size may differ among variables, depending on missing data points
b Valproate, lamotrigine, carbamazepine
c Olanzapine, quetiapine, risperidone, aripiprazole, clozapine
Treatment  modalitiesa n %
Current use of maintenance medication (n = 836)
 Lithium 590 70.6
 Anticonvulsantsb 281 33.6
 Atypical  antipsychoticsc 318 38.0
 Conventional antipsychotics 30 3.6
Ever participated in group psychoeducation (n = 836) 394 47.1
Emergency plan (n = 836) 484 57.9
Participation of a psychiatrist (n = 819) 803 98.0
Mood monitoring (n = 835) 229 27.4
Psychotherapy in the previous year (n = 681) 133 15.9
Supportive treatment (n = 809) 749 92.6
Patient reports that a treatment plan has been made (n = 825)
 Yes 502 60.8
 No 323 39.2
Patient is involved in decision-making (n = 827)
 Never 52 6.3
 Sometimes 166 20.1
 Mostly 279 33.7
 Always 330 39.9
Significant others have been asked to participate in the treatment (n = 828)
 Yes 677 81.8
 No 151 18.2
Patient uses the internet for information on bipolar disorders and treatments (n = 836)
 Yes 357 42.7
 No 479 57.3
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and eight had been admitted at least once (data missing 
in two).
Polypharmacy was common. When all medications, 
excluding benzodiazepines and somatic medications, 
were taken together, 328 (39.1%) respondents used two 
drugs, and 117 (13.9%) three or more drugs with a maxi-
mum of five. In addition to the medication already listed 
in the questionnaire, 169 (20.1%) respondents reported 
the use of an antidepressant (14.2% BD I; 35.5% BD II; 
25.0% BD NOS; 17.8% SZA). In 15 of these 169 respond-
ents (BD I n = 4; BD II = 10; BD NOS = 1) the antidepres-
sant was not combined with lithium, an anticonvulsant 
or an antipsychotic. Of the respondents using either 
lithium, valproate or carbamazepine (n = 711), almost all 
(n = 702) reported an adequate frequency of laboratory 
testing.
Psychotherapy
Of the 133 respondents that received psychotherapy 
in the previous year, 77 (57.8%) reported that the ther-
apy was specifically aimed at treating their BD, and 50 
(37.6%) reported that the therapy had another focus.
Concordance with treatment guideline
Concordance with the guideline for each treatment 
modality was as follows: participation of a psychiatrist 
in 757 of 773 respondents (97.9%), maintenance phar-
macotherapy in 754 of 786 (95.9%), supportive treat-
ment in 560 of 762 (73.5%), use of an emergency plan in 
556 of 787 (70.6%), psychotherapy in 399 of 765 (52.2%), 
group psychoeducation in 371 of 786 (47.2%), and mood 
monitoring in 369 of 785 respondents (47%). A guide-
line recommendation for maintenance pharmacotherapy 
applied to almost all respondents. In only two respond-
ents, both BD I, maintenance pharmacotherapy was not 
recommended according to the guideline, however one 
was symptomatic and therefore concordance was scored 
according to clinical profile “currently symptomatic” as 
described in Table 1. For 30 respondents, data necessary 
to determine the need for maintenance pharmacotherapy 
were either missing or inconclusive.
Factors associated with concordance
Factors associated with concordance are presented in 
Table  3. Specialization for mood disorder of treatment 
setting, whether the respondents reported that a treat-
ment plan had been made, total years of education, bipo-
lar diagnosis, whether one or more significant others had 
been asked to participate in the treatment, duration of 
illness, absence of psychiatric comorbidity, and age were 
all significantly associated with being better concordant 
with the guideline. Age and duration of illness were nega-
tively correlated with concordance (see Table 3).
In a multiple regression analysis age, absence of psychi-
atric comorbidity, duration of illness, and whether or not 
it was asked to involve significant others in the treatment, 
did not contribute significantly to the model, although 
the latter almost reached significance. All other factors 
were significant. The model explained almost 10% of vari-
ance in concordance scores (see Table 3).
Discussion
In this nationwide study of guideline concordance in 
routine clinical practice, we found that the use of main-
tenance pharmacotherapy was highly concordant with 
the recommendations in the Dutch guideline for BD. 
This resembles outcomes in some of the previous stud-
ies in euthymic or unspecified BD. The high frequency of 
lithium use (70.6%) in our study is remarkable. In a recent 
study in Denmark, lithium was prescribed less frequently, 
41.7% during a 12-year study period, and its use had 
declined over the years (Kessing et al. 2016). In contrast 
to pharmacotherapy, applying psychosocial treatments 
was much less concordant with the Dutch guideline, 
even in specialized centers for mood disorders. Especially 
the low rate of concordance with the participation in 
(group) psychoeducation is relevant since its efficacy in 
the maintenance treatment of bipolar disorder has been 
well established (Colom et al. 2003) and it is thus recom-
mended in the guideline for all BD patients. Moreover, 
group psychoeducation is widely available in the Nether-
lands. Concordance-rates for mood monitoring and psy-
chotherapy were also relatively low. For psychotherapy, 
this may be due to the fact that in the 2008 guideline the 
indications are still described in general terms. As a con-
sequence, measuring its concordance is less straightfor-
ward. Moreover, psychotherapy may have a wider focus 
than only BD, as was indicated by a considerable num-
ber of participants. Specialization of treatment center, 
years of education, type of diagnosis, and the fact that the 
patient was informed that a written treatment plan had 
been made, were all significantly associated with guide-
line concordance. This is an important finding since some 
of these factors (making a treatment plan and informing 
patients about this, and taking into account the level of 
education of patient) can be easily optimized in every-
day clinical practice. Especially the level of understand-
ing of verbal communication can easily be overestimated. 
Together with inviting a significant other to be involved 
in the treatment, these findings point in the direction 
that shared decision-making may result in more guide-
line-concordant treatments. However, little is currently 
known if and how shared decision-making may influence 
clinical outcome in mental health care (Duncan et  al. 
2010). Although significant in univariate analysis, the 
presence or absence of psychiatric comorbidity, duration 
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of illness, and age did not contribute significantly in the 
regression model. In contrast to our hypothesis, gender, 
marital status, and use of internet by the patient, were 
not associated with better concordance with the guide-
line. The involvement of the patient in decision-making 
in the treatment was also not associated with better con-
cordance, although this was probably due to the fact that 
the majority of patients stated that they were involved.
Strengths and limitations
Our study has several strong points. To the best of 
our knowledge this is a first nation-wide study that it 
includes a large number of patients in long-term psychi-
atric outpatient treatment. Moreover, concordance with 
the treatment guideline was assessed for a wide variety 
of guideline recommended treatment modalities, and 
quantified in a composite score taking into account dif-
ferent clinical profiles of patients in maintenance treat-
ment. Dennehey et al. (2005) used a composite score for 
adherence to the medication guidelines from the Texas 
Medication Algorithm Project (TMAP). This score meas-
ured visit schedules, medication/dosing, and response to 
patient symptoms. In that study a multifaceted treatment 
program including the medication guidelines was studied 
in several intervention clinics, and compared with treat-
ment as usual in non-intervention clinics. Adherence to 
the guideline was only studied in the intervention clinics. 
Kilbourne et  al. (2010) implemented composite quality 
metrics to measure the quality of processes of care from 
various treatment guidelines in a study using medical 
records, including assessments of symptoms, comorbid-
ity, cardiometabolic outcomes, and documentation of 
patient treatment experience.
Our study has several limitations. First, although a 
great effort was made to include a representative cohort 
in a wide variety of mental health care treatment settings, 
it is likely that a bias towards psychiatrists and patients 
with particular interest in our study will have occurred, 
since many participating patients were treated in spe-
cialized mood disorder centers. This will limit the gen-
eralizability of our results to non-specialized centers and 
private practice. Therefore, outcomes may reflect more 
guideline-concordant care than in settings where psychi-
atrists (and therefore their patients) did not participate 
Table 3 Demographic, illness related and  treatment related factors for  concordance with  the  Dutch guideline for  BD: 
univariate and multivariate analyses
a Univariate analysis from simple regression. Note: constants in the simple regression models with categorical factors: gender: 72.8, marital status: 72.6, diagnosis: 
72.1, psychiatric comorbidity: 72.1, treatment setting: 70.7, whether or not a treatment plan has been made: 72.0, whether or not significant others have been asked 
to participate: 71.1, patients’ involvement in decision-making: 72.6, and patients’ use of internet:  72.8
b The multivariate analysis includes all factors that are univariately associated with concordance (at the level of statistical significance of α = 0.05). The coefficient of 
determination of the multivariate model R2 = 0.09 (p < 0.001)
c Reference category
Univariate  modela Multivariate  modelb
B SE P B SE P
Demographic factors
 Gender: female (male)c − 0.65 1.38 .640
 Age − 0.15 0.06 .010 0.03 0.07 .670
 Marital status: living together or married (living alone, divorced, widowed)c 1.34 1.32 .309
 Education: total years of education 0.52 0.15 < .001 0.49 0.16 .002
Illness related factors
 Diagnosis: BD I (BD II, BD NOS or SZA)c 3.74 1.34 .005 2.98 1.43 .037
 Psychiatric comorbidity: absent (present)c 2.97 1.40 .035 2.63 1.50 .080
 Duration of illness − 0.15 0.06 .007 − 0.09 0.07 .193
Treatment related factors
 Treatment setting: specialized centers (non-specialized center)c 7.36 1.50 < .001 5.67 1.64 .001
 Patient reports that a treatment plan has been made: yes (no)c 5.65 1.32 < .001 5.37 1.44 < .001
 Significant others have been asked to participate in the treatment: yes (no)c 4.86 1.69 .004 3.43 1.81 .059
Patient is involved in decision-making: (never)c
 Sometimes − 0.08 3.09 .979
 Mostly 0.04 2.96 .989
 Always 0.67 2.92 .818
Other factor
 Patient uses the internet for information on bipolar disorder and treatments: yes (no)c 1.56 1.30 .229
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in this study. On the other hand, this could suggest that 
measures to improve guideline concordance may be 
even more vital in those settings. A second limitation is 
that maintenance pharmacotherapy was not assessed in 
detail but was defined as the use of at least one mainte-
nance drug recommended in the guideline. Whether the 
choice or dosage of medication was optimized accord-
ing to guideline recommendations, was not taken into 
account. Use of antidepressants may have been under-
reported since information was provided at the initiative 
of the respondent. As will be the case in studies using 
patient surveys, not all nuances of individual treatments 
could be included in the assessment of concordance with 
the guideline, and answers may have been incomplete or 
inconsistent. Although an updated guideline was pub-
lished in 2015, after the study was completed, we assume 
that the findings of our study are still relevant today, since 
there were no major changes in the recommendations for 
long-term treatment strategies in the 2015 guideline. The 
differences between these guidelines concern recommen-
dations in pharmacotherapy and psychological treatment 
of a more detailed level than addressed in our study.
Conclusions
Overall, we conclude that in everyday clinical practice, 
more than pharmacotherapy, the implementation of 
psychosocial treatments still needs considerable effort. 
Actively involving the patient in the treatment may 
improve concordance rates, although further research 
in this field is needed. Future studies on psychosocial 
treatments for bipolar disorder may result in more spe-
cific indications for which treatment is needed for which 
patient in which phase of the illness. Eventually, one 
can expect that a more personalized approach in treat-
ment guidelines will greatly enhance their utility and 
implementation.
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